Europe Vaccine Adjuvants Market – Size, Outlook, Trends and Forecast (2024 – 2032)

An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities.

Europe Vaccine Adjuvants Market Segments Size & Growth:

Europe vaccine adjuvants market size is projected to reach approximately $197.21 million by the end of 2024 with a CAGR of close to 12.48% from $124.28 million in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include increasing use of recombinant subunit and synthetic vaccines, Unmet Vaccine market needs for specific diseases, technological innovations and Expanding government recommendations for immunisations. However, lack of scientific awareness of adjuvants, Funding/cost of developing a new adjuvant, strict regulatory factors, high toxicity adjuvants and side effects of adjuvants are thereby hampering the market growth.

Europe Vaccine Adjuvants Market  Segments Share:

The type which comprises Aluminium Salts categorises Europe vaccine adjuvants market, Tensoactive Adjuvants, Adjuvant Emulsions, Bacteria derived Adjuvants, Liposome Adjuvants, Carbohydrate Adjuvants, among others. Among them, Adjuvant Emulsions holds the most significant share in the market. By Route of administration into oral, intradermal, and intranasal. Among them, intranasal segment holds the most significant share in the market. By the mechanism of action into active immunostimulants, carriers, and vehicle adjuvants. By Geography, Germany and U.K are expected to experience the highest growth in the forecast period due to increasing awareness in the region.

Europe Vaccine Adjuvants Market  Trends:

• Leading global biotherapeutics company CSL Limited (ASX: CSL), officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben Carroll, MP.
• Novavax, Inc. announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue.
• Agenus Inc., an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR).

Europe Vaccine Adjuvants Market  Research Report:

An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.

To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.

Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year

Identifying DROC in the current market and their impact in altering the market dynamics.

Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.

Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.

The primary market players, such as

• MPV Technologies
• Avanti Polar Lipids
• Agenus, Inc.
• Invivogen
• SPI Pharma, Inc.